Drixoral

Nasal Intubation, Rhinorrhea, Rhinitis, Allergic + 10 more

Treatment

3 FDA approvals

20 Active Studies for Drixoral

What is Drixoral

Oxymetazoline

The Generic name of this drug

Treatment Summary

Oxymetazoline is a medication used to treat facial redness, nasal and sinus congestion, and ptosis (drooping eyelids). It is available in various forms, such as over-the-counter nasal sprays, intranasal sprays for regional anesthesia during dental procedures, and ophthalmic sprays approved in July 2020 to treat ptosis. Oxymetazoline is a direct-acting alpha-adrenergic agonist, meaning it stimulates the alpha-adrenergic receptors in the body.

Afrin Original Pump Mist

is the brand name

image of different drug pills on a surface

Drixoral Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Afrin Original Pump Mist

Oxymetazoline

1975

7

Approved as Treatment by the FDA

Oxymetazoline, commonly known as Afrin Original Pump Mist, is approved by the FDA for 3 uses including Anesthesia, Conduction and Obesity .

Anesthesia, Conduction

Used to treat induction of Regional Anesthesia in combination with Tetracaine

Obesity

Used to treat weight 40 kg or more in combination with Tetracaine

Anesthesia, Conduction

Used to treat Regional Anesthesia therapy in combination with Tetracaine

Effectiveness

How Drixoral Affects Patients

Oxymetazoline is a medication that helps to narrow the blood vessels and reduce blood flow. It can also reduce nasal congestion and improve breathing in patients with a cold. In addition, studies have shown that oxymetazoline has antioxidant properties, meaning it can protect cells from damage caused by inflammation.

How Drixoral works in the body

Oxymetazoline is used to treat a variety of conditions, including rosacea, blepharoptosis, and nasal congestion. It works by binding to special receptors in the body that cause blood vessels to constrict, which reduces blood flow and swelling. This can help reduce the redness of rosacea, elevate the eyelid in blepharoptosis, and reduce nasal congestion. It is also used in combination with other medications for local anesthetic in dentistry to counteract the vasodilatory effects.

When to interrupt dosage

The measure of Drixoral is contingent upon the diagnosed affliction, including Regional Anesthesia, weight 40 kg or more and Hay Fever. The amount of dosage can be found in the table below, depending on the technique of application (e.g. Solution - Nasal or Solution).

Condition

Dosage

Administration

Sinus Congestion

, 0.5 mg/mL, 50.0 mg/mL, 0.75 mg/mL, 0.0005 mg/mL, 0.512 mg/mL, 0.5095 mg/mL, 0.5055 mg/mL, 0.000005 mL/mL, 2.0 mg/mL, 0.05 mg/mL, 0.05 %, 0.025 %, 0.05 mg, 0.5 %, 0.25 mg/mL, 0.0005 mg/mg, 0.01 mg/mg, 500.0 mg/mL, 1.0 mg/mL, 5.0 mg/mL, 1.5 mg/mL

, Nasal, Spray, Spray - Nasal, Spray, metered, Spray, metered - Nasal, Liquid, Liquid - Nasal, Oral, Spray - Oral, Topical, Liquid - Topical, Solution - Nasal, Solution, Ophthalmic, Liquid - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Cream - Topical, Cream, Spray - Topical, Solution / drops - Nasal, Kit, Kit - Topical, Jelly, Solution / drops; Spray, Solution / drops; Spray - Nasal, Solution - Ophthalmic, Nasal; Oral, Jelly - Nasal

Postoperative Hemorrhage

, 0.5 mg/mL, 50.0 mg/mL, 0.75 mg/mL, 0.0005 mg/mL, 0.512 mg/mL, 0.5095 mg/mL, 0.5055 mg/mL, 0.000005 mL/mL, 2.0 mg/mL, 0.05 mg/mL, 0.05 %, 0.025 %, 0.05 mg, 0.5 %, 0.25 mg/mL, 0.0005 mg/mg, 0.01 mg/mg, 500.0 mg/mL, 1.0 mg/mL, 5.0 mg/mL, 1.5 mg/mL

, Nasal, Spray, Spray - Nasal, Spray, metered, Spray, metered - Nasal, Liquid, Liquid - Nasal, Oral, Spray - Oral, Topical, Liquid - Topical, Solution - Nasal, Solution, Ophthalmic, Liquid - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Cream - Topical, Cream, Spray - Topical, Solution / drops - Nasal, Kit, Kit - Topical, Jelly, Solution / drops; Spray, Solution / drops; Spray - Nasal, Solution - Ophthalmic, Nasal; Oral, Jelly - Nasal

Nasal Intubation

, 0.5 mg/mL, 50.0 mg/mL, 0.75 mg/mL, 0.0005 mg/mL, 0.512 mg/mL, 0.5095 mg/mL, 0.5055 mg/mL, 0.000005 mL/mL, 2.0 mg/mL, 0.05 mg/mL, 0.05 %, 0.025 %, 0.05 mg, 0.5 %, 0.25 mg/mL, 0.0005 mg/mg, 0.01 mg/mg, 500.0 mg/mL, 1.0 mg/mL, 5.0 mg/mL, 1.5 mg/mL

, Nasal, Spray, Spray - Nasal, Spray, metered, Spray, metered - Nasal, Liquid, Liquid - Nasal, Oral, Spray - Oral, Topical, Liquid - Topical, Solution - Nasal, Solution, Ophthalmic, Liquid - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Cream - Topical, Cream, Spray - Topical, Solution / drops - Nasal, Kit, Kit - Topical, Jelly, Solution / drops; Spray, Solution / drops; Spray - Nasal, Solution - Ophthalmic, Nasal; Oral, Jelly - Nasal

Rhinorrhea

, 0.5 mg/mL, 50.0 mg/mL, 0.75 mg/mL, 0.0005 mg/mL, 0.512 mg/mL, 0.5095 mg/mL, 0.5055 mg/mL, 0.000005 mL/mL, 2.0 mg/mL, 0.05 mg/mL, 0.05 %, 0.025 %, 0.05 mg, 0.5 %, 0.25 mg/mL, 0.0005 mg/mg, 0.01 mg/mg, 500.0 mg/mL, 1.0 mg/mL, 5.0 mg/mL, 1.5 mg/mL

, Nasal, Spray, Spray - Nasal, Spray, metered, Spray, metered - Nasal, Liquid, Liquid - Nasal, Oral, Spray - Oral, Topical, Liquid - Topical, Solution - Nasal, Solution, Ophthalmic, Liquid - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Cream - Topical, Cream, Spray - Topical, Solution / drops - Nasal, Kit, Kit - Topical, Jelly, Solution / drops; Spray, Solution / drops; Spray - Nasal, Solution - Ophthalmic, Nasal; Oral, Jelly - Nasal

Rhinitis, Allergic

, 0.5 mg/mL, 50.0 mg/mL, 0.75 mg/mL, 0.0005 mg/mL, 0.512 mg/mL, 0.5095 mg/mL, 0.5055 mg/mL, 0.000005 mL/mL, 2.0 mg/mL, 0.05 mg/mL, 0.05 %, 0.025 %, 0.05 mg, 0.5 %, 0.25 mg/mL, 0.0005 mg/mg, 0.01 mg/mg, 500.0 mg/mL, 1.0 mg/mL, 5.0 mg/mL, 1.5 mg/mL

, Nasal, Spray, Spray - Nasal, Spray, metered, Spray, metered - Nasal, Liquid, Liquid - Nasal, Oral, Spray - Oral, Topical, Liquid - Topical, Solution - Nasal, Solution, Ophthalmic, Liquid - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Cream - Topical, Cream, Spray - Topical, Solution / drops - Nasal, Kit, Kit - Topical, Jelly, Solution / drops; Spray, Solution / drops; Spray - Nasal, Solution - Ophthalmic, Nasal; Oral, Jelly - Nasal

Obesity

, 0.5 mg/mL, 50.0 mg/mL, 0.75 mg/mL, 0.0005 mg/mL, 0.512 mg/mL, 0.5095 mg/mL, 0.5055 mg/mL, 0.000005 mL/mL, 2.0 mg/mL, 0.05 mg/mL, 0.05 %, 0.025 %, 0.05 mg, 0.5 %, 0.25 mg/mL, 0.0005 mg/mg, 0.01 mg/mg, 500.0 mg/mL, 1.0 mg/mL, 5.0 mg/mL, 1.5 mg/mL

, Nasal, Spray, Spray - Nasal, Spray, metered, Spray, metered - Nasal, Liquid, Liquid - Nasal, Oral, Spray - Oral, Topical, Liquid - Topical, Solution - Nasal, Solution, Ophthalmic, Liquid - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Cream - Topical, Cream, Spray - Topical, Solution / drops - Nasal, Kit, Kit - Topical, Jelly, Solution / drops; Spray, Solution / drops; Spray - Nasal, Solution - Ophthalmic, Nasal; Oral, Jelly - Nasal

Nasal Congestion

, 0.5 mg/mL, 50.0 mg/mL, 0.75 mg/mL, 0.0005 mg/mL, 0.512 mg/mL, 0.5095 mg/mL, 0.5055 mg/mL, 0.000005 mL/mL, 2.0 mg/mL, 0.05 mg/mL, 0.05 %, 0.025 %, 0.05 mg, 0.5 %, 0.25 mg/mL, 0.0005 mg/mg, 0.01 mg/mg, 500.0 mg/mL, 1.0 mg/mL, 5.0 mg/mL, 1.5 mg/mL

, Nasal, Spray, Spray - Nasal, Spray, metered, Spray, metered - Nasal, Liquid, Liquid - Nasal, Oral, Spray - Oral, Topical, Liquid - Topical, Solution - Nasal, Solution, Ophthalmic, Liquid - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Cream - Topical, Cream, Spray - Topical, Solution / drops - Nasal, Kit, Kit - Topical, Jelly, Solution / drops; Spray, Solution / drops; Spray - Nasal, Solution - Ophthalmic, Nasal; Oral, Jelly - Nasal

Acquired Blepharoptosis

, 0.5 mg/mL, 50.0 mg/mL, 0.75 mg/mL, 0.0005 mg/mL, 0.512 mg/mL, 0.5095 mg/mL, 0.5055 mg/mL, 0.000005 mL/mL, 2.0 mg/mL, 0.05 mg/mL, 0.05 %, 0.025 %, 0.05 mg, 0.5 %, 0.25 mg/mL, 0.0005 mg/mg, 0.01 mg/mg, 500.0 mg/mL, 1.0 mg/mL, 5.0 mg/mL, 1.5 mg/mL

, Nasal, Spray, Spray - Nasal, Spray, metered, Spray, metered - Nasal, Liquid, Liquid - Nasal, Oral, Spray - Oral, Topical, Liquid - Topical, Solution - Nasal, Solution, Ophthalmic, Liquid - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Cream - Topical, Cream, Spray - Topical, Solution / drops - Nasal, Kit, Kit - Topical, Jelly, Solution / drops; Spray, Solution / drops; Spray - Nasal, Solution - Ophthalmic, Nasal; Oral, Jelly - Nasal

Anesthesia, Conduction

, 0.5 mg/mL, 50.0 mg/mL, 0.75 mg/mL, 0.0005 mg/mL, 0.512 mg/mL, 0.5095 mg/mL, 0.5055 mg/mL, 0.000005 mL/mL, 2.0 mg/mL, 0.05 mg/mL, 0.05 %, 0.025 %, 0.05 mg, 0.5 %, 0.25 mg/mL, 0.0005 mg/mg, 0.01 mg/mg, 500.0 mg/mL, 1.0 mg/mL, 5.0 mg/mL, 1.5 mg/mL

, Nasal, Spray, Spray - Nasal, Spray, metered, Spray, metered - Nasal, Liquid, Liquid - Nasal, Oral, Spray - Oral, Topical, Liquid - Topical, Solution - Nasal, Solution, Ophthalmic, Liquid - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Cream - Topical, Cream, Spray - Topical, Solution / drops - Nasal, Kit, Kit - Topical, Jelly, Solution / drops; Spray, Solution / drops; Spray - Nasal, Solution - Ophthalmic, Nasal; Oral, Jelly - Nasal

Rosacea

, 0.5 mg/mL, 50.0 mg/mL, 0.75 mg/mL, 0.0005 mg/mL, 0.512 mg/mL, 0.5095 mg/mL, 0.5055 mg/mL, 0.000005 mL/mL, 2.0 mg/mL, 0.05 mg/mL, 0.05 %, 0.025 %, 0.05 mg, 0.5 %, 0.25 mg/mL, 0.0005 mg/mg, 0.01 mg/mg, 500.0 mg/mL, 1.0 mg/mL, 5.0 mg/mL, 1.5 mg/mL

, Nasal, Spray, Spray - Nasal, Spray, metered, Spray, metered - Nasal, Liquid, Liquid - Nasal, Oral, Spray - Oral, Topical, Liquid - Topical, Solution - Nasal, Solution, Ophthalmic, Liquid - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Cream - Topical, Cream, Spray - Topical, Solution / drops - Nasal, Kit, Kit - Topical, Jelly, Solution / drops; Spray, Solution / drops; Spray - Nasal, Solution - Ophthalmic, Nasal; Oral, Jelly - Nasal

Anesthesia, Conduction

, 0.5 mg/mL, 50.0 mg/mL, 0.75 mg/mL, 0.0005 mg/mL, 0.512 mg/mL, 0.5095 mg/mL, 0.5055 mg/mL, 0.000005 mL/mL, 2.0 mg/mL, 0.05 mg/mL, 0.05 %, 0.025 %, 0.05 mg, 0.5 %, 0.25 mg/mL, 0.0005 mg/mg, 0.01 mg/mg, 500.0 mg/mL, 1.0 mg/mL, 5.0 mg/mL, 1.5 mg/mL

, Nasal, Spray, Spray - Nasal, Spray, metered, Spray, metered - Nasal, Liquid, Liquid - Nasal, Oral, Spray - Oral, Topical, Liquid - Topical, Solution - Nasal, Solution, Ophthalmic, Liquid - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Cream - Topical, Cream, Spray - Topical, Solution / drops - Nasal, Kit, Kit - Topical, Jelly, Solution / drops; Spray, Solution / drops; Spray - Nasal, Solution - Ophthalmic, Nasal; Oral, Jelly - Nasal

Airway visualization

, 0.5 mg/mL, 50.0 mg/mL, 0.75 mg/mL, 0.0005 mg/mL, 0.512 mg/mL, 0.5095 mg/mL, 0.5055 mg/mL, 0.000005 mL/mL, 2.0 mg/mL, 0.05 mg/mL, 0.05 %, 0.025 %, 0.05 mg, 0.5 %, 0.25 mg/mL, 0.0005 mg/mg, 0.01 mg/mg, 500.0 mg/mL, 1.0 mg/mL, 5.0 mg/mL, 1.5 mg/mL

, Nasal, Spray, Spray - Nasal, Spray, metered, Spray, metered - Nasal, Liquid, Liquid - Nasal, Oral, Spray - Oral, Topical, Liquid - Topical, Solution - Nasal, Solution, Ophthalmic, Liquid - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Cream - Topical, Cream, Spray - Topical, Solution / drops - Nasal, Kit, Kit - Topical, Jelly, Solution / drops; Spray, Solution / drops; Spray - Nasal, Solution - Ophthalmic, Nasal; Oral, Jelly - Nasal

persistent facial erythema

, 0.5 mg/mL, 50.0 mg/mL, 0.75 mg/mL, 0.0005 mg/mL, 0.512 mg/mL, 0.5095 mg/mL, 0.5055 mg/mL, 0.000005 mL/mL, 2.0 mg/mL, 0.05 mg/mL, 0.05 %, 0.025 %, 0.05 mg, 0.5 %, 0.25 mg/mL, 0.0005 mg/mg, 0.01 mg/mg, 500.0 mg/mL, 1.0 mg/mL, 5.0 mg/mL, 1.5 mg/mL

, Nasal, Spray, Spray - Nasal, Spray, metered, Spray, metered - Nasal, Liquid, Liquid - Nasal, Oral, Spray - Oral, Topical, Liquid - Topical, Solution - Nasal, Solution, Ophthalmic, Liquid - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Cream - Topical, Cream, Spray - Topical, Solution / drops - Nasal, Kit, Kit - Topical, Jelly, Solution / drops; Spray, Solution / drops; Spray - Nasal, Solution - Ophthalmic, Nasal; Oral, Jelly - Nasal

Warnings

Drixoral has one contraindication and should not be consumed when experiencing the conditions detailed in the following table.

Drixoral Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Oxymetazoline may interact with Pulse Frequency

There are 20 known major drug interactions with Drixoral.

Common Drixoral Drug Interactions

Drug Name

Risk Level

Description

Antazoline

Major

The absorption of Antazoline can be decreased when combined with Oxymetazoline.

Azelastine

Major

The absorption of Azelastine can be decreased when combined with Oxymetazoline.

Beclomethasone dipropionate

Major

The absorption of Beclomethasone dipropionate can be decreased when combined with Oxymetazoline.

Betamethasone

Major

The absorption of Betamethasone can be decreased when combined with Oxymetazoline.

Budesonide

Major

The absorption of Budesonide can be decreased when combined with Oxymetazoline.

Drixoral Toxicity & Overdose Risk

The toxic dose of oxymetazoline in rats is 680 micrograms per kilogram when taken orally and 1630 micrograms per kilogram when taken subcutaneously. In mice, the toxic dose is 4700 micrograms per kilogram when taken orally, 48 milligrams per kilogram when taken intraperitoneally, and 34 milligrams per kilogram when taken subcutaneously. Accidental overdose in both children and adults has caused dizziness, chest pain, headaches, heart attack, stroke, vision problems, irregular heartbeat, high or low blood pressure, sleepiness, and even coma. Rebound congestion

Drixoral Novel Uses: Which Conditions Have a Clinical Trial Featuring Drixoral?

Thirteen active studies are examining the potential of Drixoral to provide Nasal Congestion relief, Ear Conduction Anesthesia and other benefits.

Condition

Clinical Trials

Trial Phases

Postoperative Hemorrhage

7 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3

persistent facial erythema

0 Actively Recruiting

Rhinorrhea

0 Actively Recruiting

Anesthesia, Conduction

0 Actively Recruiting

Rosacea

0 Actively Recruiting

Acquired Blepharoptosis

0 Actively Recruiting

Anesthesia, Conduction

0 Actively Recruiting

Airway visualization

0 Actively Recruiting

Nasal Congestion

0 Actively Recruiting

Rhinitis, Allergic

0 Actively Recruiting

Nasal Intubation

0 Actively Recruiting

Obesity

631 Actively Recruiting

Not Applicable, Phase 2, Phase 4, Phase 1, Early Phase 1, Phase 3

Sinus Congestion

0 Actively Recruiting

Drixoral Reviews: What are patients saying about Drixoral?

5

Patient Review

10/12/2009

Drixoral for Seasonal Runny Nose

This medication has been a life-saver for me. It quickly and effectively clears up my symptoms, which is more than I can say for other medications I've tried. Unfortunately, it seems like Walmart no longer carries it and that it's no longer being made. Are there any other places where I can get this medication?

5

Patient Review

9/24/2010

Drixoral for Seasonal Runny Nose

I've used this for over 15 years, and I need it now! It's really effective, but I can't seem to find it anywhere. Why has it been discontinued?

5

Patient Review

8/12/2012

Drixoral for Non-Seasonal Allergic Runny Nose

This is the only thing that has worked on my non-allergic rhinitis. I bought it from a Canadian pharmacy a few years ago, but they don't carry it anymore.

5

Patient Review

9/2/2008

Drixoral for Inflammation of the Nose due to an Allergy

5

Patient Review

3/25/2011

Drixoral for Cold Symptoms

We need to know if this drug is available under another name.

5

Patient Review

10/3/2011

Drixoral for Allergic Conjunctivitis

This decongestant is amazing! It quickly dried up my sinuses and the effects lasted for at least 12 hours, if not more.

3.3

Patient Review

11/15/2011

Drixoral for Stuffy Nose

I'm glad this medication is available in Canada now. It's been effective for me with no negative consequences that I've noticed.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about drixoral

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Why was Drixoral taken off the market?

"At present, Drixoral is not available on the US market due to manufacturing changes by the company Merck. According to Merck's updated website, they do not expect the product to be available in 2010."

Answered by AI

What is Drixoral used for?

"Decongestants help to reduce swelling in the nose.

This medication is used to temporarily relieve symptoms caused by the common cold, flu, allergies, or other breathing illnesses. Antihistamines help relieve watery eyes, itchy eyes/nose/throat, runny nose, and sneezing. Decongestants help reduce swelling in the nose."

Answered by AI

What are the side effects of Drixoral?

"Some common side effects of Adderall include blurred vision, dizziness, lightheadedness, drowsiness, high blood pressure, nervousness, and palpitations."

Answered by AI

Can you still get Drixoral?

"Drixoral is unavailable at the moment but it hasn't been permanently taken off the market, according to Schering-Plough. "We are currently in the process of changing manufacturing locations," says Julie Lux, a company spokesperson."

Answered by AI

Clinical Trials for Drixoral

Image of VA Greater Los Angeles Healthcare System, West Los Angeles, CA in West Los Angeles, United States.

Treatment for Obesity

Any Age
All Sexes
West Los Angeles, CA

Women Veterans are the fastest growing segment of VA users, with most users in midlife. This dramatic growth has created challenges for VA to ensure that appropriate services are available to meet women Veterans' needs, and that they will want and be able to use those services. Furthermore, few VA improvement efforts have focused on women Veterans' health and health care in midlife. The EMPOWER QUERI 3.0 Program is a cluster randomized type 3 hybrid implementation-effectiveness trial testing two strategies designed to support implementation and sustainment of evidence-based practices for women Veterans in at least 18 VA facilities from 4 regions.

Waitlist Available
Has No Placebo

VA Greater Los Angeles Healthcare System, West Los Angeles, CA

Alison B Hamilton, PhD MPH

Image of Brigham and Womens Hospital in Boston, United States.

Chia Seeds for Breastfeeding

18 - 45
All Sexes
Boston, MA

The investigators' over-arching hypothesis is that mechanical and compositional properties of chia seeds supplemented during lactation diminish obesity-induced intestinal inflammation and barrier dysfunction. The investigators hypothesize these changes will result in: 1) reduced maternal systemic inflammation (serum CRP and IL-6) and increased gut microbial diversity and richness, 2) reduced HM fat and inflammatory markers, metrics the research team have demonstrated differ in tandem with maternal metabolic health and 3) improved infant growth/body composition. To test these hypotheses, investigators will evaluate chia seed supplementation during lactation in a 6wk multi-site pilot RCT (Aim 1) and through translational studies using human enteroids (Aim 2).

Waitlist Available
Has No Placebo

Brigham and Womens Hospital (+1 Sites)

David A Fields, Phd

Have you considered Drixoral clinical trials?

We made a collection of clinical trials featuring Drixoral, we think they might fit your search criteria.
Go to Trials
Image of Public Health Research Center: Clinical Exercise Research Center in Columbia, United States.

Pistachio Snacking for Obesity

25 - 45
All Sexes
Columbia, SC

The purpose of this study is to evaluate the effects of pistachio snacking on metabolic flexibility (at rest, during exercise, and in post-exercise recovery) in healthy overweight and obese adults. Secondary goals include evaluating effects on changes in diet quality, sleep characteristics, physical activity, and hormonal health in women. In randomized order, participants will complete four days of pistachio snacking and four days of normal dietary habits (control). For both conditions, primary outcomes of resting substrate metabolism, metabolic flexibility during exercise, and post-exercise substrate metabolism will be measured pre-post intervention via indirect calorimetry. Secondary outcome of diet quality (kcal, carb, fat, protein) will be measured pre-post intervention via diet log. Exploratory outcomes of daily physical activity (steps, intensity), nightly sleep characteristics (quantity, quality, latency, efficiency), and daytime sleepiness and hunger.

Recruiting
Has No Placebo

Public Health Research Center: Clinical Exercise Research Center

Katie R Hirsch, PhD

Image of People Science in Los Angeles, United States.

CLB101 for Gut Health in Obesity

18 - 65
All Sexes
Los Angeles, CA

Anaerostipes caccae CLB101TM️ is a next-generation probiotic isolated from healthy humans. It was shown to be in decreased abundance in people with protein-based food sensitivities/allergies. CLB101TM️ is different from most commercially available probiotics in that it directly produces butyrate. Butyrate is a naturally occurring small molecule found in the gut of healthy individuals, and it has been shown to provide clinical benefits including strengthening the gut lining, providing immune health, and supporting a balanced microbiome. The rationale for developing CLB101TM️ is to provide a probiotic that generates butyrate in the targeted intestinal locations where it can optimally benefit cells that line the gut.

Waitlist Available
Paid Trial

People Science

Naoh Craft, MD

ClostraBio Inc.

Have you considered Drixoral clinical trials?

We made a collection of clinical trials featuring Drixoral, we think they might fit your search criteria.
Go to Trials
Image of Miles Square Health Center Chicago in Chicago, United States.

Food is Medicine for High Blood Pressure and Obesity

Any Age
All Sexes
Chicago, IL

The goal of this clinical trial is to treat both hypertension and obesity in adults using a food is medicine framework. Participants will be randomized 1:1 to FIM+DASH or usual-care control. The 24-week trial includes a 12-week FIM+DASH intervention followed by a 12-week maintenance period and leverages existing partnerships with community-based organizations for home food delivery and culinary skill-skill building. The main questions it aims to answer are: (1) What is the effect of FIM+DASH vs. usual care control on blood pressure? (2) What is the effect of FIM+DASH vs. usual care control on DASH diet adherence (diet quality), body weight, and waist circumference? (3) How to identify factors associated with the sustainability and scalability of FIM+DASH in real-world settings?

Phase 2
Waitlist Available

Miles Square Health Center Chicago (+3 Sites)

Image of Local Restaurant Site in Bryan, United States.

Menu Labeling for Healthy Habits and Diet

18+
All Sexes
Bryan, TX

This study evaluates the impact of culturally tailored menu labeling interventions on psychosocial factors and ordering behavior among customers in two independently owned Hispanic restaurants in East-Central Texas. Participants will be exposed to one of three sequential menu conditions at each restaurant: (1) a standard menu without nutrition information, (2) a paper menu with bilingual nutrition labels, or (3) a digital menu app enhanced with Augmented Reality (AR) and Artificial Intelligence (AI) providing interactive nutrition guidance. The study will assess whether menu formats influence nutrition literacy, decision-making confidence, self-efficacy, attitudes, behavioral intentions, and actual ordering behavior. Data will be collected through surveys, purchase receipts, and app interaction logs.

Recruiting
Has No Placebo

Local Restaurant Site

Hyunjung Lee, PhD

Have you considered Drixoral clinical trials?

We made a collection of clinical trials featuring Drixoral, we think they might fit your search criteria.
Go to Trials